CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma

[1]  E. Oki,et al.  CD44v3,8‐10 is essential for Slug‐dependent vimentin gene expression to acquire TGF‐β1‐induced tumor cell motility , 2022, Cancer science.

[2]  F. Mégraud,et al.  Leukaemia Inhibitory Factor (LIF) Inhibits Cancer Stem Cells Tumorigenic Properties through Hippo Kinases Activation in Gastric Cancer , 2020, Cancers.

[3]  F. Mégraud,et al.  TAZ Controls Helicobacter pylori-Induced Epithelial–Mesenchymal Transition and Cancer Stem Cell-Like Invasive and Tumorigenic Properties , 2020, Cells.

[4]  F. Mégraud,et al.  Verteporfin targeting YAP1/TAZ‐TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells , 2020, International journal of cancer.

[5]  A. Bode,et al.  CELF2 suppresses non-small cell lung carcinoma growth by inhibiting the PREX2-PTEN interaction. , 2019, Carcinogenesis.

[6]  F. Mégraud,et al.  Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination , 2019, Cancers.

[7]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[8]  A. Matheu,et al.  Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer , 2018, Therapeutic advances in medical oncology.

[9]  Y. Cho,et al.  ESRP1‐Induced CD44 v3 Is Important for Controlling Pluripotency in Human Pluripotent Stem Cells , 2018, Stem cells.

[10]  Jiansheng Wang,et al.  miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  F. Mégraud,et al.  Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma , 2016, Clinical Cancer Research.

[12]  G. Taylor,et al.  Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture , 2016, Gut.

[13]  J. Kusukawa,et al.  CD44v3+/CD24− cells possess cancer stem cell-like properties in human oral squamous cell carcinoma , 2015, International journal of oncology.

[14]  D. Wei,et al.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target , 2015, Stem cells translational medicine.

[15]  P. Bragado,et al.  Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.

[16]  F. Mégraud,et al.  Helicobacter pylori generates cells with cancer stem cell properties via epithelial–mesenchymal transition-like changes , 2014, Oncogene.

[17]  M. Salto‐Tellez,et al.  CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. , 2014, Cancer research.

[18]  Hai-gang Li,et al.  Expression of CD44v3, Erythropoietin and VEGF-C in Gastric Adenocarcinomas: Correlations with Clinicopathological Features , 2014, Tumori.

[19]  M. Biffoni,et al.  CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. , 2014, Cell stem cell.

[20]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[21]  C. Staedel,et al.  Helicobacter pylori Initiates a Mesenchymal Transition through ZEB1 in Gastric Epithelial Cells , 2013, PloS one.

[22]  Y. Nie,et al.  Identification of CD44+ cancer stem cells in human gastric cancer. , 2013, Hepato-gastroenterology.

[23]  Claude C. Warzecha,et al.  Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). , 2012, Seminars in cancer biology.

[24]  D. Huntsman,et al.  De novo expression of CD44 variants in sporadic and hereditary gastric cancer , 2010, Laboratory Investigation.

[25]  A. Fukamizu,et al.  Role of Kenae/CCDC125 in cell motility through the deregulation of RhoGTPase. , 2009, International journal of molecular medicine.

[26]  T. Wang,et al.  Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.

[27]  M. Isamat,et al.  Conservation of CD44 exon v3 functional elements in mammals , 2008, BMC Research Notes.

[28]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[29]  A. Barbour,et al.  Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. , 2003, Cancer research.

[30]  P. Herrlich,et al.  CD44: From adhesion molecules to signalling regulators , 2003, Nature Reviews Molecular Cell Biology.

[31]  J. Sleeman,et al.  CD44 is required for two consecutive steps in HGF/c-Met signaling. , 2002, Genes & development.

[32]  M. Hung,et al.  Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth* , 2001, The Journal of Biological Chemistry.

[33]  H. Kuniyasu,et al.  Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  V. Kosma,et al.  Expression of CD44 and its variant isoform v3 has no prognostic value in gastric cancer , 2001, Histopathology.

[35]  L. Bourguignon,et al.  CD44 Interaction with Tiam1 Promotes Rac1 Signaling and Hyaluronic Acid-mediated Breast Tumor Cell Migration* , 2000, The Journal of Biological Chemistry.

[36]  E. Gherardi,et al.  Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met* , 1999, The Journal of Biological Chemistry.

[37]  L. Bourguignon,et al.  Rho-kinase (ROK) promotes CD44v(3,8-10)-ankyrin interaction and tumor cell migration in metastatic breast cancer cells. , 1999, Cell motility and the cytoskeleton.

[38]  D. Gotley,et al.  Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. , 1998, Cancer research.

[39]  R. Cardiff,et al.  CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. , 1998, Journal of cellular physiology.

[40]  A. Ariza,et al.  Expression of CD44H and CD44v3 in normal oesophagus, Barrett mucosa and oesophageal carcinoma. , 1996, Journal of clinical pathology.

[41]  B Z Levi,et al.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.

[42]  K. Bennett,et al.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor , 1995, The Journal of cell biology.

[43]  S. Fox,et al.  Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. , 1994, Cancer research.

[44]  J. Bos,et al.  A PCR-based method for the analysis of human CD44 splice products. , 1993, PCR methods and applications.

[45]  J. Bell,et al.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.